Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)-Reference-Cited by-同舟云学术

Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

Published:2004-01 Issue:1 Volume:34 Page:4-9
ISSN:0001-2998
Container-title:Seminars in Nuclear Medicine
language:en
Short-container-title:Seminars in Nuclear Medicine

Author:

Borghaei Hossein,Schilder Russell J

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging

Reference21 articles.

1. Rituximab;Cheson;Expert Opin Biol Ther,2002

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma;McLaughlin;J Clin Oncol,1998

3. High-dose rituximab therapy in chronic lymphocytic leukemia;Keating;Semin Oncol,2000

4. Radiolabeled anti-CD-20 monoclonal antibodies for the treatment of B-cell lymphoma;Dillman;J Clin Oncol,2002

5. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL);Witzig;Proc Am Soc Clin Oncol,2003

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of 90Y Sorption with Nanodiamonds as Potential Carriers in the Radiopharmaceutical Composition;Radiochemistry;2022-01

2. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma;International Journal of Molecular Sciences;2020-07-30

3. Radioimmunotherapy;Clinical Nuclear Medicine;2020

4. Radiothérapie;Pharmacie Clinique Pratique en Oncologie;2020

5. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide;Toxicon;2019-06